Griffiths, Robert I <br/><br/>
Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.  [electronic resource] 

 -  Cancer  Dec 2012 
 - 6079-88 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.27638  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cost-Benefit Analysis<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Prognosis<br/>Quality-Adjusted Life Years<br/>Rituximab<br/>SEER Program<br/>Survival Rate